CTNM (Contineum Therapeutics) Total Assets: $250.37 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTNM Contineum Therapeutics Inc CTNM
17 GF Score
Price $15.46
! 2 Warning Signs
View Full Analysis

What is Contineum Therapeutics Total Assets?

Contineum Therapeutics CTNM -1.37% 17 Total Assets is $250.37 Mil as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Contineum Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $250.37 Mil.

During the past 12 months, Contineum Therapeutics's average Total Assets Growth Rate was 98.80% per year. During the past 3 years, the average Total Assets Growth Rate was 59.40% per year.

During the past 5 years, Contineum Therapeutics's highest 3-Year average Total Assets Growth Rate was 74.80%. The lowest was 59.40%. And the median was 67.10%.

Total Assets is connected with ROA %. Contineum Therapeutics's annualized ROA % for the quarter that ended in Jun. 2026 was -23.69%. Total Assets is also linked to Revenue through Asset Turnover. Contineum Therapeutics's Asset Turnover for the quarter that ended in Jun. 2026 was 0.00.

Contineum Therapeutics  (NAS:CTNM) Total Assets Explanation

Total Assets is connected with ROA %.

Contineum Therapeutics's annualized ROA % for the quarter that ended in Jun. 2026 is

ROA %=Net Income (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=-60.616/( (261.349+250.367)/ 2 )
=-60.616/255.858
=-23.69 %

Note: The Net Income data used here is four times the quarterly (Jun. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Contineum Therapeutics's Asset Turnover for the quarter that ended in Jun. 2026 is

Asset Turnover
=Revenue (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=0/( (261.349+250.367)/ 2 )
=0/255.858
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Contineum Therapeutics Total Assets Related Terms

Contineum Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Contineum Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics Total Assets Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
70.52 50.64 130.39 212.85 276.64

Contineum Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 182.89 190.85 276.64 261.35 250.37
CTNM
17GF Score
Contineum Therapeutics Inc CTNM
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Contineum Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Contineum Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=260.989+15.653
=276.64

Contineum Therapeutics's Total Assets for the quarter that ended in Jun. 2026 is calculated as

Total Assets=Total Equity (Q: Jun. 2026 )+Total Liabilities (Q: Jun. 2026 )
=239.66+10.707
=250.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $250.37 Mil mean?
Contineum Therapeutics (CTNM) has a Total Assets of $250.37 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Contineum Therapeutics and its competitors.
Is Contineum Therapeutics' Total Assets too high?
Contineum Therapeutics' current Total Assets is $250.37 Mil. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' Total Assets compare to FDMT and PRME?
Contineum Therapeutics' Total Assets of $250.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Contineum Therapeutics and its competitors. Contineum Therapeutics's current Total Assets is $250.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current Total Assets of $250.37 Mil. The current Total Assets is $250.37 Mil. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current Total Assets is $250.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Contineum Therapeutics Business Description

Address 3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score

Get the complete analysis for CTNM

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.46
Price